45% of Australians will suffer from a mental illness in their lifetime…

What are we going to do about it? 

A new paradigm for mental health

Mind Medicine Australia is a charity that enables the development of regulatory-approved and research-backed psychedelic-assisted psychotherapy for the treatment of mental ill-health in Australia.


About 15% of the world’s population (1.1 billion people) currently have a mental illness[i]. In Australia, mental illness is the leading cause of non-fatal disease burden, and the third leading cause of total disease burden[ii], and nearly half of all Australians will experience a mental illness at some point in their lives[iii]. If you are not affected, someone dear to you is likely to be. In addition, the direct cost of mental illness in Australia is at least $28.6 billion annually[iv]. While certain treatments have helped a minority of sufferers in a sustainable way, the vast global effort to understand and treat mental illness over the past many decades has yielded inadequate outcomes.
  1. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2016
  2. AIHW 2016. Australian Burden of Disease Study: impact and causes of illness and death in Australia 2011. Australian Burden of Disease Study series no. 3. Cat. No. BOD 4. Canberra: AIHW
  3. Australian Bureau of Statistics. (2009). National Survey of Mental Health and Wellbeing: Summary of Results, 4326.0, 2007. ABS: Canberra
  4. Medibank Private Limited and Nous Group. (2013). The Case for Mental Health Reform in Australia: A Review of Expenditure and System Design

a new paradigm

The past decade has seen renewed interest and progress in psychedelic-assisted therapies. In rigorous and well-controlled clinical trials, psychedelic-assisted psychotherapy (using classical psychedelics such as psilocybin, and related compounds such as MDMA) has produced remarkable clinical outcomes for individuals suffering with addiction[i], depression[ii], end-of-life distress[iii], and Post Traumatic Stress Disorder[iv]. Preliminary and currently active trials are investigating additional applications, for example within obsessive compulsive disorder and autism. About one hundred psychedelic and MDMA research trials have recently been completed or are currently active. Results from clinical trials have been so compelling that the US Food and Drug Administration (FDA) recently designated psilocybin- and MDMA-assisted psychotherapies as ‘breakthrough therapies’, expediting their research and development.
  1. Johnson, M et al. (2014). 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28-11:983-992.
  2. Carhart-Harris et al. (2016). Psilocybin with psychological support for treatment-resistant depression. The Lancet, 3-7:619-627.
  3. Griffiths, R. R. et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of psychopharmacology, 30(12), 1181-1197.
    AND Ross et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30-12:1165-1180.
  4. M.C. Mithoefer, T.M. Wagner, A.T. Mithoefer, L. Jerome, R. Doblin, The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study, J. Psychopharmacol. 25 (4) (2011) 439–452.


For largely political reasons, psychedelic research and therapy has been substantially constrained since 1970. However, the past decade has seen a resurgence in psychedelic research, alongside a decline in associated stigmas, and an increase in interest within the general population, the scientific community, and politics. While over one hundred psychedelic trials have been conducted over the past decade, Australia’s first clinical trial – run by PRISM and St Vincent’s Hospital, and co-sponsored by Mind Medicine Australia – is only just kicking off in 2019. We are seeing the emergence of a different paradigm in mental health treatment, with early yet mounting evidence indicating impressive outcomes. This is an historic moment in mental health research and treatment. It is time for Australia to join this exploration.


Mind Medicine Australia is a registered charity (with DGR-1 status) acting as the central node for the promotion of regulatory-approved and research-backed psychedelic medicines to assist with the treatment of mental health in Australia. 

We support innovation in the treatment of mental health and in the promotion of psychological wellbeing through the development of regulatory approved psychedelic medicines. We will do this by acting as a nexus between academia, government, medical practitioners, technology, philanthropy and culture.


Mind Medicine Australia acts as a nexus between academia, clinicians, regulators and culture. We facilitate research with our sister organisation Psychedelic Research in Science and Medicine (PRSIM) and other research partners.


By developing relationships between government, academic institutions, interest groups and regulatory bodies, Mind Medicine Australia aims to facilitate evidence-based change.

Education & events

Mind Medicine Australia creates educational content on the topic of mental health and the potential of psychedelic medicines. We showcase the latest innovations in the treatment of mental health at our live events, online and our future conference.


Mind Medicine Australia will act as the interface between research and practice by translating clinical research into accredited therapist training protocols.

Launch Event of Mind Medicine Australia

We celebrated the launch of Mind Medicine Australia on 13th February 2019 with a  community of Australian changemakers at The University of Melbourne. 

University of Melbourne Logo
Close Menu